Name: Z-DEVD-FMK
Brand: Selleck Chemicals
SKU: S7312
Availability: InStock
Rating: 5 (102 reviews)

Jump to

Quality Control

Batch: Purity: 99.95%

99.95

Related Targets	Bcl-2 PD-1/PD-L1 Ferroptosis p53 Apoptosis related Synthetic Lethality STAT TNF-alpha Ras KRas
Other Caspase Inhibitors	Emricasan (IDN-6556) Z-VAD-FMK Q-VD-Oph Belnacasan (VX-765) Z-IETD-FMK Ac-DEVD-CHO Z-LEHD-FMK TFA Z-VAD(OH)-FMK PAC-1 Z-YVAD-FMK

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
duck embryo fibroblasts (DEFs)	Function assay		2 h	effectively promoted viral replication	30813500
OSCC cell	Apoptosis assay	20 µM	48 h	reduce the activity of caspase 3 and caspase 9	30573978
A549	Function assay	25 μM	24 h	significantly inhibit ROS generation in A549 cells	30240709
HCT116 cells	Function assay	50 μM	2 h	cotreatment with Xylopine to prevente the xylopine-induced increasing apoptosis	29362667
K562 cells	Function assay		2 h	increased R. verniciflua extract-induced cell proliferation	29328387
THP-1 cells	Function assay	50 μM	2 h	sub-G1 peak Inhibition in DMQA induced cell death	29225136
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (149.55 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	2%DMSO 1 30%PEG400 2 5%Tween80 3 63%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.000mg/ml (1.50mM)	Taking the 1 mL working solution as an example, add 20 μL of 50 mg/ml clarified DMSO stock solution to 300 μL of PEG 400, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 630 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	668.66	Formula	C₃₀H₄₁FN₄O₁₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	210344-95-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Caspase-3 Inhibitor			Smiles	CC(C)C(C(=O)NC(CC(=O)OC)C(=O)CF)NC(=O)C(CCC(=O)OC)NC(=O)C(CC(=O)OC)NC(=O)OCC1=CC=CC=C1

Mechanism of Action

Targets/IC₅₀/Ki	Caspase-3
In vitro	Z-DEVD-FMK (1–200 μM) inhibits D4-GDI cleavage and apoptosis in a concentration-dependent manner. This compound reduces ceramide-induced cardiomyocyte death and significantly inhibits the activation of caspase 3. It (100μM) attenuates OxyHb-induced cell detachment, reduced caspase-2 and -3 activities, abolishes OxyHb-induced DNA ladders, and prevents OxyHb-induced cleavage of PARP in cultured brain microvessel endothelial cells. This chemical (100 μM) blocks MPP+-induced increases in caspase-3 enzyme activity. It dose dependently blocks 6-OHDA-induced apoptotic cell death with IC50 of 18 μM.
Kinase Assay	Caspase activity assay
Kinase Assay	Caspase-3 and caspase-9 activities are measured using fluorescent-based substrate. After treatment, the cells are resuspended in lysis buffer (50 mM Tris HCl, 1 mM EDTA, and 10 mM EGTA) containing 10 mM digitonin for 20 min at 37°C. Supernatants are treated with either of the fluorogenic substrates Ac-DEVD-AFC for caspase-3 or Ac-LEHD-AFC for caspase-9 for 1 h at 37°C and fluorescence is measured at excitation at 400 nm and emission at 505 nm using a Gemini XS fluorescence plate reade
In vivo	Z-DEVD-FMK, before and after injury, markedly reduces post-traumatic apoptosis, and significantly improved neurological recovery.
References	[1] https://pubmed.ncbi.nlm.nih.gov/9485209/ [2] https://pubmed.ncbi.nlm.nih.gov/9295387/ [3] https://pubmed.ncbi.nlm.nih.gov/10997751/ [4] https://pubmed.ncbi.nlm.nih.gov/11157197/ [5] https://pubmed.ncbi.nlm.nih.gov/17045926/

Applications

Methods	Biomarkers	Images	PMID
Western blot	ORF57 / caspase 7 / caspase 3 CLK3 / ADH4 / MDH1 HAUSP / Kinesin 5B / GEP100 / SDCCAG3 / PARD3 / Lamin A/C / PARP		20159985

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Z-DEVD-FMK Caspase-3 inhibitor

Chemical Structure

Molecular Weight: 668.66